MGA’s Alex Brill on CNBC’s Squawk Box

Jul 26, 2019 | Interviews

MGA’s Alex Brill on CNBC’s Squawk Box On ‘Squawk Box’ today, Alex Brill discusses the second quarter GDP growth: “I think its a solid [GDP] number. Obviously, the inventory piece creates a little bit of volatility, and the investment numbers are a...

Conservative Thinkers Share Their Views for Biosimilars in a Post-ACA, BPCIA Landscape

Jul 24, 2019 | News

Conservative Thinkers Share Their Views for Biosimilars in a Post-ACA, BPCIA Landscape Allison Inserro | The Center for Biosimilars “Would legislators take the opportunity to redo some parts of the BPCIA, if they had the chance? Both [Alex] Brill and Hayes said...

Shortened Exclusivity Could Save $31B

Jul 16, 2019 | News

Shortened Exclusivity Could Save $31B Alex Brill was recently quoted by Politico Pro about MGA’s recent “Gamesmanship and Other Barriers to Drug Competition” paper: “Brand-name medicines’ market exclusivity periods have climbed an average...

MGA’s Alex Brill on CNBC’s Squawk Box

Jul 9, 2019 | Interviews

MGA’s Alex Brill on CNBC’s Squawk Box Today, Brill discusses President Trump’s potential appointment options for the Federal Reserve Board of Governors. Watch Here

Biologics are Not Natural Monopolies

Jul 2, 2019 | Op-Eds

Biologics are not Natural Monopolies Alex Brill and Benedic N. Ippolito | Health Affairs Blog Recently, several physicians and health policy analysts took to the Health Affairs blog to propose what was, to anyone who has been following biosimilars for the...